Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia | Zendy

Tait D. Shanafelt | Zendy; Xin V. Wang | Zendy; Neil E. Kay | Zendy; Curtis A. Hanson | Zendy; Susan O’Brien | Zendy; Jacqueline C. Barrientos | Zendy; Diane F. Jelinek | Zendy; Esteban Braggio | Zendy; José F. Leis | Zendy; Cong C. Zhang | Zendy; Steven Coutré | Zendy; Paul M. Barr | Zendy; Amanda F. Cashen | Zendy; Anthony R. Mato | Zendy; Avina K. Singh | Zendy; Michael P. Mullane | Zendy; Richard F. Little | Zendy; Harry P. Erba | Zendy; Richard M. Stone | Zendy; Mark R. Litzow | Zendy; Martin S. Tallman | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia

Author(s) -

Tait D. Shanafelt,

Xin V. Wang,

Neil E. Kay,

Curtis A. Hanson,

Susan O’Brien,

Jacqueline C. Barrientos,

Diane F. Jelinek,

Esteban Braggio,

José F. Leis,

Cong C. Zhang,

Steven Coutré,

Paul M. Barr,

Amanda F. Cashen,

Anthony R. Mato,

Avina K. Singh,

Michael P. Mullane,

Richard F. Little,

Harry P. Erba,

Richard M. Stone,

Mark R. Litzow,

Martin S. Tallman

Publication year - 2019

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1817073

Subject(s) - ibrutinib , chemoimmunotherapy , medicine , rituximab , fludarabine , chronic lymphocytic leukemia , obinutuzumab , hazard ratio , ofatumumab , interim analysis , oncology , ighv@ , cyclophosphamide , idelalisib , leukemia , confidence interval , clinical trial , chemotherapy , lymphoma

Data regarding the efficacy of treatment with ibrutinib-rituximab, as compared with standard chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab, in patients with previously untreated chronic lymphocytic leukemia (CLL) have been limited.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research